Multiple myeloma
Conditions
Interventions
Group of tandem autologous stem-cell transplantation:Double ASCT
Group of allogeneic stem-cell transplantation:Allo-SCT
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Between 18 and 60 years old; 2) Patients who meet the 2014 IMWG multiple myeloma diagnostic criteria; 3) Patients with 4 or more prognostic scores according to the first part of the study; 4) Symptomatic, measurablenewly diagnosed MM patients; 5) ECOG behavior status between 0-3 level; expected survival time> 6 months; 6) Did not receive any anti-tumor therapy before (except glucocorticoid alone); 7) No other malignancy history; 8) No other serious illnesses in conflict with this program; 9) Patients understand and are willing to participate in this clinical trial and provide signed informed consent; 10) All patients must agree to take effective contraceptives during the study and in the termination of treatment within 6 months, women of childbearing age must be negative in the pregnancy test before treatment.
Exclusion criteria
Exclusion criteria: 1) Have participated in other clinical studies in the last 3 months; 2) Secondary myeloma after chemotherapy or radiotherapy of other malignant tumors; 3) Received treatment for multiple myeloma before enrollment (except glucocorticoid alone); 4) Any other malignancy history before or at the time of diagnosis; 5) Decompensated heart failure, dilated cardiomyopathy, ECG showed significant reduction in ST segment of coronary heart disease and myocardial infarction occurred in the last 6 months; 6) Patients with uncontrolled severe infection or organic disease; 7) Liver dysfunction (transaminase exceeds the normal value limit of 4 times and / or blood bilirubin > 2.0mg / dl); 8) Have brain disorders or severe mental illness; 9) Lactating or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy rate;overall survival;minimal residual disease; | — |
Countries
China
Contacts
Public ContactJuan Li
The First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed